GlassScriptPhysician profile
Marc M Levinson
NPI 1942226741
$642.42
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $169.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $156.56 | 2019-2020 | |
| Daiichi Sankyo INC. | $125.00 | 2019 | |
| Endo Pharmaceuticals INC. | $81.57 | 2019 | |
| Collegium Pharmaceutical, INC. | $80.34 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $45.59 | 2019 | |
| Redhill Biopharma INC. | $34.28 | 2020 | |
| Shionogi INC | $32.08 | 2019 | |
| Sentynl Therapeutics, INC. | $31.34 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $24.93 | 2019 | |
| Antares Pharma, INC. | $16.46 | 2020 | |
| Horizon Therapeutics Plc | $14.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Levinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.